 AIM ImmunoTech Inc NYSEAMERICAN:AIM said it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability, and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events SAE. The company, which also reported no SAEs in Cohort 1, said the study will proceed with enrollment into Cohort 3. 